Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (August 2020)
32 slides from Genprex's investor presentation, Aug 3, 2020
Slide 1: Reprogramming the Course of Cancer and Diabetes
©) Genprex REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘Statements containein this presentation regaaing meters that are not historical fats ate Yorwars-lookingstatements within the meaning ofthe Private Secutes Ltigoten RetormAcrot 1995, Because uch statements are subject risks ang uncertainties acual este may offer material
Slide 3: Executive Summary
EXECUTIVE SUMMARY COMPETITIVE ADVANTAGES + MARKET GAPS AND UNMET NEED + CLINICAL ACHIEVEMENT + FDA FAST TRACK DESIGNATION + COMBINATION TRIALS WITH TOP SELLING DRUGS + STRONG BALANCE SHEET
Slide 4: 21st Century Gene Therapies
21ST CENTURY GENE THERAPIES ‘TECHNOLOGY EQUIPPED TO CHANGE THE FUTURE OF PATIENT CARE WHO WE ARE Genprex, Inc. Isa clinical-stage gene therapy company developing life- ‘changing gene therapies for patients with cancer and diabetes, expanding their access to new treatment options. MARKET GAPS AND UNM
Slide 5: Company Highlights: Key Clinical Achievements
COMPANY HIGHLIGHTS KEY CLINICAL ACHIEVEMENTS. ‘TARGETS TUMOR CELLS Interim data from a Phase | clinical trial show GPX-001 (quaratusugene ozeplasmid) selectively and preferentially targets primary and metastatic tumor cells, and a Maximum Tolerated Dose was established. 78% DISEASE CONTROL RATE Inte
Slide 6: Company Highlights: Key Corporate Achievements
COMPANY HIGHLIGHTS KEY CORPORATE ACHIEVEMENTS FAST TRACK DESIGNATION Received Fast Track Designation for GPX-001 + Tagrisso® for NSCLC in January 2020. ‘STRONG BALANCE SHEET Well positioned with a strengthened balance sheet, which will support R&D efforts. EXTENSIVE IP PORTFOLIO Hold extensive, worl
Slide 7: Fast Track Designation
FAST TRACK DESIGNATION Genprex received Fast Track Designation for GPX.001 + EGFR inhibitor osimertinib (AstraZeneca’s Tagrisso®) for NSCLC patients that progressed on cosimertinib alone. ‘Tagrisso® had $38+ worldwide gross ssales in 2019, and it is AZs highest ‘grossing product. FTD is for therapie
Slide 8: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE PATHWAY TO APPROVAL PRECLINICAL unica unica ‘cuNIcAL Puasen Prase2 Puases "AUTO-IMMUNE DISEA‘ FT us ronan race Deseaton Nasaaq: GNPX
Slide 9: Bridging Gaps in Modern Medicine
BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS INCOLOGY ‘O-IMMUNE DISEASES NON-SMALL CELL LUNG CANCER ‘* Genprex’s oncology combination treatment approach utilizes targeted therapies and immunotherapies. ‘* Planned clinical trials include combinations with osimertin
Slide 10: Slide 10
Slide 11: Non-Small Cell Lung Cancer
NON-SMALL CELL LUNG CANCER MARKET STATISTICS MOST L%.. CANCER TAGRISSO® 2019 SALES NSCLC represents the majority of all lung cancers. ‘AstraZenece’s highest grossing product. WORLDWIDE CASES KEYTRUDA® 2019 SALES Almost two million cases per year worldwide. Merck's highest grossing product. NITED STA
Slide 12: Problem: Few Patients Benefit from Modern Therapies
PROBLEM: FEW PATIENTS BENEFIT FROM MODERN THERAPIES LIMITATIONS TO NSCLC TREATMENT TARGETED THERAPIES IMMUNOTHERAPIES PATIENT ELIGIBILITY Of patients havean activating OF patients areeligiblefor EGFR mutation and can benefit ‘and benefit from from targeted therapies! mmunotherapies? “Drug resistance
Slide 13: Solution: Novel Platform to Treat Cancer
SOLUTION: NOVEL PLATFORM TO TREAT CANCER ONCOPREX™ NANOPARTICLE DELIVERY PLATFORM GENES Multiple tumor @| eet ce suppressor genes proach peers combination therapy CANCERS Genetic mutations found in other cancers Genprex ‘Nasdaq: GNPX
Slide 14: Oncoprex Nanoparticle Delivery Platform
ONCOPREX™ NANOPARTICLE DELIVERY PLATFORM CATIONIC LIPID NANOVESICLE CARRIES DRUG TO TUMORS. Positively charged hanovesile er Cassete S) (S) i} Negatively charged cancer cell Nanovesicle attaches to Cancer‘killing genes Cell death cancer cell like amagnet —_integrate into coll Our non-viral, biodegra
Slide 15: GPX-001 Targets Cancer at Its Core
GPX-001 TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS — MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Nasaaq: GNPX
Slide 16: GPX-001 Inhibits Key Cell Signaling
GPX-001 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS. Coll Survival Proliferation Nasaaq: GNPX
Slide 17: GPX-001 Affects Tumor Immunogenicity
GPX-001 AFFECTS TUMOR IMMUNOGENICITY TUSC2 ALSO SHOWN TO UPREGULATE NK AND CD8+ T CELLS, AND DOWNREGULATE PD-L1 RECEPTORS eV ve 20 ILS < is Immature Mature NK cells NK cells Nasaaq: GNPX
Slide 18: GPX-001 Monotherapy
GPX-001 MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase | monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=3 Maximum Tolerated
Slide 19: GPX-001 + Erlotinib Combination
GPX-001 + ERLOTINIB COMBINATION PHASE II PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS: PATIENT EGFR STAT NSE | PRIOR THERAPY RLNE OE Pestive exon 1812) cr chemo 3 Negatwe 24s eression Target Lesion chemo /ant-201 2 Negative oe ee Chemo /ant.P01 6 ostive (exon 2) / Tumor Rereson Ent ;
Slide 20: GPX-001 + Erlotinib Combination: Swimmer Plot
EGFR status/mutation GPX-001 + ERLOTINIB COMBINATION ‘Swimmer Plot of Best Response, with Time on Study Negative 4 sD Negative 4 Positive (exon 18+20) 4 Negative 4 Negative + Negative 4 Negative + Negative 4 Positive (exon 21 Negative Negative 4 Positive (exon 21) 4 * Chemotherapy ‘4 Chemotherapy+im
Slide 21: GPX-001 Shows Synergy with Immunotherapies
GPX-001 SHOWS SYNERGY WITH IMMUNOTHERAPIES TUSC2 IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER ‘Survival on Lung Metastasis Mode! HHEEE 0 6 Ea % bays. , i os ‘TUSC2+anti-PD1 combination significantly prolonged TUSC2+anti-PD1 exhibit greater antitumor activity than RIRIN/All
Slide 22: GPX-001 Shows Synergy with Immunotherapies
GPX-001 SHOWS SYNERGY WITH IMMUNOTHERAPIES TUSC2 IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER TUSC2 + PEMBRO TUSC2 + PEMBRO+ CHEMO Strong antitumor immune responses of anti-PD1 ‘TUSC2+anti-PD1+chemo combination resulted were found against PDX tumors developed in in metastas
Slide 23: Auto-Immune Disease Program
AUTO-IMMUNE DISEASE PROGRAM
Slide 24: Diabetic Patients in Need of Modern Therapy
DIABETIC PATIENTS IN NEED OF MODERN THERAPY GPX-002 MAY ELIMINATE NEED FOR INSULIN IN DIABETIC PATIENTS Type 1 and Type 2 diabetes affect approximately 34 million people in the U.S, or 10 percent of the U.S. population. May replace daily burden of blood glucose ‘monitoring and insulin replacement th
Slide 25: GPX-002 Replenishes Levels of Insulin
sR @ kon GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an AAV vector to deliver the Pdxi and MafAgenes to the pancreas. Transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are
Slide 26: Key Milestones Through Early 2021
KEY MILESTONES THROUGH EARLY 2021 CLINICAL + Continue preparations for combination clinical trials of GPX-001 wth Tagrisso® and Keytruda®, respect planning to initiate thes 2021 RESEARCH & DEVELOPMENT Pursue non-proprietary drug name and + Conduct additional pre-clinical research brand drug name for
Slide 27: Targeted Cancer Companies
TARGETED CANCER COMPANIES Company smo. | EXCHANGE INDICATION Det caneunerancey Inara fesdandNea, = Tans rove rasang “Cove nee Crone sionepeits ceva, NSEC Cronk pra vai Teepeutes aT waseag — NSCLGSOMREHL AE! yer au seven pray SK fsnq _SoldTumors ukemi. na ata, TumingPoine voxneeglaa en rspant ae sg N
Slide 28: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman & Chief Executive Officer + 30+ years of expertise in corporate law including corporate governance, in biotech industry + Former owner of securities broker dealer frm MICHAEL REDMAN, Executive VP & Chief Operating Officer + 30+ years.f expe
Slide 29: Meet Our Team: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD JACK A. ROTH MD, FACS, Chairman PASI ANTERO JANNE MD, PhD + Professorand Bud Johnson Distinguished Clinical Chair, Department of Thoracicand Cardiovascular Surgery, Chief, Section of Thoracic Melecular Oncology; Professor of Molecular and Cellular + Professor
Slide 30: Meet Our Team: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board + 30+ years of expertise in corporate law, including ‘orporate governance, in biotech industry + Former owner of securities broker dealer frm JOSE A, MORENO TOSCANO Board Director + Chief Executive Officer, LFB USAne + 20+ year
Slide 31: We Believe
WE BELIEVE IN A FUTURE OF TRANSFORMATIONAL PATIENT CARE 215" CENTURY GENE THERAPIES MARKET GAPS AND UNMET NEED COMBINATION TRIALS WITH TOP SELLING DRUGS SCALING UP MANUFACTURING EXPLORING NEW INDICATIONS AND PARTNERSHIPS Nasaaq: GNPX
Slide 32: Genprex
oO Genprex NASDAQ: GNPX 1601 Trinity St, Bldg B, #3.312.09, Austin, Texas 78712 (877)774-GNPX | investors@genprex.com Nasaaq: GNPX